Wnt/beta-catenin-IN-6 is an orally active Wnt/beta-catenin pathway inhibitor. Wnt/beta-catenin-IN-6 blocks the AKT/GSK-3beta/beta-catenin signaling pathway, leading to reduced expression of Wnt target genes (c-Myc, c-Jun). Wnt/beta-catenin-IN-6 reduces COX2 expression and IL-8 levels, highlighting its dual anti-inflammatory and antitumor effects. Wnt/beta-catenin-IN-6 serves as a tool for non-small cell lung cancer (NSCLC) research[1].